248 related articles for article (PubMed ID: 19863336)
1. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract][Full Text] [Related]
2. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
8. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
10. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
Tam CS
Leuk Lymphoma; 2009 Oct; 50(10):1557-8. PubMed ID: 19757304
[No Abstract] [Full Text] [Related]
11. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
13. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
[TBL] [Abstract][Full Text] [Related]
15. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
18. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
20. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Petrizzi VB; Ricci F; Crugnola M; Spriano M; Spedini P; Ilariucci F; Uziel L; Attolico I; Vismara E; De Blasio A; Zaccaria A; Morra E
Blood; 2011 Oct; 118(15):4079-85. PubMed ID: 21772050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]